1-Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock's comprehensive textbook of psychiatry. 9th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009. P. 1432-556.
2-Sadock BG, Sadock VA, eds. Kaplan & Sadock's synopsis of psychiatry: behavioral science/clinical psychiatry. 10th ed. Philadelphia: Wolter Kluwer/Lippincott, Williams & Wilkins; 2007. P. 123-6 .
3-Goff DC,
Midha KK,
Sarid-Segal O,
Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995;117(4):417-23.
4-Shoja-Shafti S. [Effectiveness of citalopram alprazolam, clomipramine in amelioration of negative symptoms in schizopherenia]. J Rehabilitation 2003;3(12):42-9. [In Persian]
5-Melle I, Johannesen J, friis S,
Haahr U,
Joa I,
Larsen TK, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 2006;163(5):800-4.
6-Gelder MG, Harrison PJ, Cowen Ph. Shorter oxford textbook of Psychiatry. 5th ed. Oxford: Oxford University Press; 2006. P. 267-306.
7-Silver H, Aharon N, Kaplan A. Add-on Fluvoxamine improves primary negative symptoms evidence for specificity from response analysis of individual symptoms. Schizophr Bull 2003;29(3):541-6.
8-Erhart SM, Marder SR,
Carpenter WT. Treatment of Schizophrenia Negative Symptoms: Future Prospects. Schizophr Bull 2006;32(2):234-7.
9-Shoja-Shafti S, Bakhtiari M. [Evaluation of prevalance of negetive symptoms in1% inpatients Schizophrenic ]. J Rehabilitation 2003;3(10):38-47. [In Persian]
10-Siris SG, Mason SE, Bermanzohn PC, Alvir JM,
McCorry TA. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol Bull 1990;26(1):91-4.
11-Raedler TJ, Jahn H,
Arlt J,
Kiefer F,
Schick M,
Naber D, et al. Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 2004;19(6):366-9.
12-Salokangas RK, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996;94(3):175-80.
13-
Taiminen TJ1,
Syvälahti E,
Saarijärvi S,
Niemi H,
Lehto H,
Ahola V, et al. Citalopram as an adjuvant in schizophrenia: Furthur evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol1997;12(1):31-5.
14-Thakore JH, Berti C, Dinan TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Pychiatr Scand 1996;94(3):194-7.
15-Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18(5):399-403 .
16-Sardarpur Sh, Arbabi M. Efficacy of naltroxan in treatment of schizophrenia.A double- blind, placebo-controlled clinical trial. Iran Clin Psychiatr J 2006;12(1):49-54.[In Persian]
17-Phayezi B. Efficacy of selgilin in schizophrenia negative symptoms.A double- blind study. Iran Clin Psychiatr 2008;14(2):131-139. [In Persian]
18-Maleki M, Javidi Z, Kiafar B, Saadatian V, Saremi AK. Depression in vitiligo patients. Q J Fundamentals Mental Health 2005;7(25-26):5-11. [In Persian]
19-Sepehri AA,
Potvin S,
Elie R,
Stip E.
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta- analysis. J Clin Psychiatr 2007;68(4):604-10.
20-Takahashi H, Sugita T, Higuchi H, Shimizu T. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol 2002;17(2):95-8.
21-Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998;18(3):208-11.
22-Lee MS, Han CS, You YW, Kim SH. Co-adminstration of sertraline and haloperidol. Psychiatry Clin Neurosci 1998;52:S193-8.
23-Singh SP,
Singh V,
Kar N,
Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta- analysis. Br J Psychiatry 2010;197(3):174-9.
24-Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: Future prospects. Schizophr Bull 2006;32(2):234-7.
25-Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 2003;18(6):305-313.
26-Nazari Nasab M, Khajeddin N, Shanesaz AA, Pezeshki A. [Evaluation of typical antipsychotic augmentation with citalopram in reduction of negative symptoms in inpatient schizophrenia in Ahvaz Golestan Hospital]. Jundishapur Sci Med J 2012;11(4):439-48. [In Persian]
